Finance

Lists
Why is TRDA up 9,78%?
Dive Deeper
TRDA:NASDAQ
Entrada Therapeutics Inc
5,44 USD
+9,78%
(+0,49) 1D
18-ноя., 10:00:51 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRDA...
Open
4,94 USD
High
5,48 USD
Low
4,81 USD
Mkt. cap
213,17 млн
Avg. vol.
471,31 миң
Volume
14,45 миң
52-wk high
16,45 USD
52-wk low
4,11 USD
EPS
-3,84 USD
Beta
-0,19
Shares outstanding
39,15 млн
No. of employees
152
Open
4,94 USD
High
5,48 USD
Low
4,81 USD
Mkt. cap
213,17 млн
Avg. vol.
471,31 миң
Volume
14,45 миң
52-wk high
16,45 USD
52-wk low
4,11 USD
EPS
-3,84 USD
Beta
-0,19
Shares outstanding
39,15 млн
No. of employees
152
News stories
From web sources and news partners
About Entrada Therapeutics Inc
CEO-
Employees152
Founded2016
HeadquartersБостон, Массачусетс, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Analyst ratings
Based on 5 analysts giving stock ratings to TRDA in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for TRDA in the last 3 months.
Highest
Current 5,44 USD
25,00 USD (+359,14%)
Average
17,75 USD (+225,99%)
Lowest
10,00 USD (+83,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
13,00 USD
+138,8%
11/18/2026
Ram Selvaraju
H.C. Wainwright
Hold
Reiterated
-
-
11/12/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
10,00 USD
+83,7%
11/06/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
25,00 USD
+359,1%
10/15/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
23,00 USD
+322,4%
09/03/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/05/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/07/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
-
-
04/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
2026-ж. сен.
Revenue
1,30 млн
875,00 миң
898,00 миң
905,00 миң
Cost of goods sold
32,26 млн
33,05 млн
35,37 млн
32,37 млн
Cost of revenue
32,26 млн
33,05 млн
35,37 млн
32,37 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,35 млн
10,12 млн
10,49 млн
10,22 млн
Operating expense
9,35 млн
10,12 млн
10,49 млн
10,22 млн
Total operating expenses
41,61 млн
43,18 млн
45,86 млн
42,59 млн
Operating income
-40,31 млн
-42,30 млн
-44,96 млн
-41,69 млн
Other non operating income
-
-
-
-
EBT including unusual items
-39,07 млн
-39,68 млн
-42,73 млн
-39,72 млн
EBT excluding unusual items
-37,17 млн
-39,68 млн
-42,73 млн
-39,72 млн
Income tax expense
92,00 миң
38,00 миң
35,00 миң
27,00 миң
Effective tax rate
-0,24%
-0,10%
-0,08%
-0,07%
Other operating expenses
-
-
-
-
Net income
-39,16 млн
-39,72 млн
-42,76 млн
-39,74 млн
Net profit margin
-3 014,93%
-4 539,09%
-4 762,03%
-4 391,38%
Earnings per share
-0,94
-0,95
-1,01
-0,94
Interest and investment income
3,14 млн
2,62 млн
2,24 млн
1,97 млн
Interest expense
-
-
-
-
Net interest expenses
3,14 млн
2,62 млн
2,24 млн
1,97 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-39,42 млн
-41,50 млн
-44,12 млн
-41,02 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google колдонмолору